Swiss contract manufacturer of peptides and oligonucleotides used in drugs, including GLP-1 obesity/diabetes medicines.
Swiss contract manufacturer of peptides and oligonucleotides used in drugs, including GLP-1 obesity/diabetes medicines.
Makes peptides, short chains of amino acids, to order for drugmakers, from small clinical batches through to commercial supply, with the commercial stage earning the most once a drug is approved. Demand has been driven by makers of GLP-1 medicines, so large commercial programmes weigh heavily. It has been building large new capacity in Switzerland.
In one line: A peptide-focused CDMO, like a smaller Lonza specializing in peptides.
Moat: narrow (process know-how, customer qualification, scale). Large-scale, regulatory-qualified peptide-synthesis capacity is hard and slow to replicate.
Headquarters: Bubendorf, Switzerland · Founded: 1971 · Employees: 2,511
Size Bachem (BANB.SW) is a Switzerland Health Care company (Pharmaceuticals: Major) with a market value of $7.06B, the 44th largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 79.35 on 18 Nov 2026.
Performance Over six months the shares fell 0.4%, against -1.8% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue grew 4.5% over the last twelve months (peer median +12.5%); the operating margin is 19.4% (peer median 13.1%).
Valuation It trades at 32.4× forward earnings against a peer median of 17.3× (3rd most expensive of 15).
Capital Return on invested capital runs 1.9 points above its cost of capital (5.0% WACC).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 709M | CHF 695M | CHF 605M | CHF 577M | CHF 532M |
| Revenue growth | — | +15% | +5% | +9% | — |
| Gross profit | CHF 191M | CHF 200M | CHF 183M | CHF 177M | CHF 171M |
| EBITDA | CHF 190M | CHF 190M | CHF 175M | CHF 166M | CHF 160M |
| Net income | CHF 149M | CHF 149M | CHF 120M | CHF 112M | CHF 101M |
| Free cash flow | -CHF 47.4M | -CHF 48.2M | -CHF 127M | -CHF 13.8M | -CHF 45.9M |
| Capital expenditure | CHF 348M | CHF 329M | CHF 285M | CHF 268M | CHF 142M |
| Total debt | n/a | CHF 57.4M | CHF 290,000 | CHF 401,000 | CHF 691,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Bachem BANB.SW | $7.06B | 0% | +5% | 19% | 32.4× | n/a |
| Lonza LONN.SW | $53.9B | +36% | -11% | 25% | 36.1× | 15.6% |
| PolyPeptide PPGN.SW | $1.61B | +7% | +22% | 7% | 52.1× | n/a |
| Novo Nordisk A/S NOVO-B.CO | $177B | -6% | +6% | 48% | 11.8× | -0.5% |
| Siegfried SFZN.SW | $3.51B | -17% | +4% | 16% | 16.8× | n/a |
| Wuxi Apptec 2359.HK | $64.1B | +51% | +38% | 44% | 19.5× | 8.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BANB.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.7% | +2.2% | 8th lowest of 21 |
| 6-month return | -0.4% | -1.8% | 10th highest of 20 |
| Distance from 52-week high | -7.7% | -20.5% | 6th highest of 21 |
| Revenue growth (TTM) | +4.5% | +12.5% | 6th lowest of 18 |
| Operating margin | 19.4% | 13.1% | 4th highest of 19 |
| Forward P/E | 32.4× | 17.3× | 3rd most expensive of 15 |
| ROIC minus cost of capital | +1.9 pp | +0.2 pp | 9th highest of 19 |
| EV / EBITDA | 32.2× | 20.5× | 4th most expensive of 10 |
| Net debt / EBITDA | 0.8× | 3.0× | 5th least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Bachem BANB.SW | Switzerland | $7.06B | 0% | +5% | 19% | 32.4× | n/a | n/a |
| Asymchem Laboratories (Tianjin) 6821.HK | Hong Kong | $7.10B | +17% | +24% | 17% | 24.4× | n/a | n/a |
| Akeso 9926.HK | Hong Kong | $7.01B | -48% | +42% | -25% | n/a | n/a | n/a |
| ImmunityBio IBRX | United States | $7.13B | -17% | +121% | -150% | n/a | n/a | n/a |
| Cytokinetics CYTK | United States | $7.15B | -35% | +30% | -625% | n/a | n/a | n/a |
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 15.3× | -6.8% | +10.8% |
| Corcept Therapeutics CORT | United States | $7.42B | +15% | +30% | 12% | 15.3× | 23.9% | +16.6% |
| Huadong Medicine 000963.SZ | China | $6.69B | -18% | +2% | 9% | 12.5× | -3.9% | +5.3% |
| Alkem Laboratories ALKEM.NS | India | $6.69B | -5% | +13% | 17% | 27.3× | 25.0% | +10.7% |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.47B | +75% | +58% | 14% | 56.6× | 10.4% | +45.5% |
| Grifols GRF.MC | Spain | $7.48B | +19% | +1% | 16% | 13.1× | 7.1% | +7.1% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% | +18.4% |
| Shanghai Fosun Pharmaceutical (Group) 600196.SS | China | $7.57B | -14% | +8% | 6% | 14.8× | 2.9% | +6.6% |
| Apotex Health APTX.TO | Canada | $6.56B | n/a | +4% | 32% | 19.3× | -11.9% | +4.2% |
| Amneal Pharmaceuticals AMRX | United States | $7.62B | +79% | +9% | 16% | 19.2× | 17.2% | +8.7% |
| Oruka Therapeutics ORKA | United States | $6.49B | +58% | n/a | n/a | n/a | n/a | n/a |
| Samsung Epis 0126Z0.KS | South Korea | $6.49B | -31% | n/a | 12% | 23.8× | n/a | n/a |
| Belite Bio, Inc. ADR BLTE | United States | $6.41B | +9% | n/a | n/a | n/a | n/a | n/a |
| Alkermes Public ALKS | United States | $7.87B | +27% | +15% | 5% | n/a | 32.5% | +7.3% |
| Biocon BIOCON.NS | India | $6.31B | -15% | +6% | 8% | 61.3× | n/a | n/a |
| RemeGen 688331.SS | China | $6.28B | -24% | +272% | 61% | 10.8× | 1.1% | +303.3% |